Return to Clinical Trials Search Results

Prospective Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

Primary endpoint: To prospectively validate a gene expression and/or mutation profile to predict the risk of recurrence associated with primary cSCC tumors Secondary endpoints: To further develop a gene expression profile assay through use of gene expression data, including that from subgroups within the cohort, to improve performance of the signature by additional algorithms or discovery of new associated genes; to use gene expression data to evaluate prediction of response to contemporary therapies

Recruitment Status

Current Studies